Ravi Patel

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

M. Pegram, Tadeusz Pieńkowski, Donald W. Northfelt et al. · JNCI Journal of the National Cancer Institute · 2004 · 271 citations · Full text

Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer

Edith A. Perez, Charles L. Vogel, David Irwin et al. · Journal of Clinical Oncology · 2001 · 248 citations

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

RS Finn, JP Crown, István Láng et al. · Cancer Research · 2012 · 128 citations

Breast Oncology, Pharmacotherapy, Tumor Biology +18

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

John A. Glaspy, David H. Henry, Ravi Patel et al. · European Journal of Cancer · 2005 · 90 citations

Darbepoetin Alfa, Medicine, Metronomic Therapy +4